2Kirst HA, Sides GD. Minirevews:New directions for macrolide antibiotics:structure modification and in vitro activity. Antimicrob Agents Cbemother,1989,33:1413.
3Kirst HA, Sides GD. New directions for macrolide antibiotics: pbarmacokinetics and clinical efficacy. Antimicrob Agents Chemother, 1989,33:1419.
4Chu S Y, Setnnello L T, Bunnell S T, et al. Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral dosc. Antimicrob Agents Chemother.1992,36:2447.
5Hardy D J. Swanson R N, Rode RA. et al. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-bydroxy-clarithromycin, ts major metabolite in humans. Antimicrob Agents Chemother,1990.34: 1407.
6Kohno Y, Yoshida H.Suwa T, et al.Comparative pharmacokinetics of clarrthromycin(TE-031). a new macrolide autibiotic, and erythromycin in rats. Antimicrob Agents Chemothe, 1989.33: 751.
7Parish L C, Clarithromycin study group. Clarithromycin in the treatment of skin and skin structure infections: two multicenter clinical studies. Int J Dermatol,1993,32(7); 528.
8Bradbury F. Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection. J Antimicrob Chemother, 1993,31(Sappl E): 153.
9Muller O. Comparison of azithromycin versus clarithromycin in the treatment of patients with upper respiratory tract infections. J Antimicrob Chemother. 1993.31(Suppl E): 137.
10Benson C A, Segreti J, Beaudette F E, et al. In vitro activity of A-56268 (TE031), a new macrolide, compared with that of erythromycin and clindamycin against selecled gram-positive and gram-negative organisms. Antimicrob Agents Chemotber, 1987,31:328.
1Chu SY, Sennether LT, Bunnell ST, et al. Pharmacoki_ netics of clarithromycin, a new marcrolide, affer singleascending ascending oral dose[J]. Antimicrob Agents Chemother, 1992, 36： 2 447.
2Hardy DJ, Swanson RN, Rode RA, et al. Enhancement of the in vitro and vivo activities of clarithromycin ag_ainst haemophilus influenzae by 14-hydroxy-clarifh_ romycin, ts major metabo lite in humans[J]. Antimicr_ob Agents Chemother, 1990, 34： 1 407.
3Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Manag_ ement of cormmunity-acquired pneumonia in the eraof penumococcal resistance a report from the drug-resistant stretococcus pneumoniae therapeutic working group[J]. Arch, Lntern Med, 2000, 160（ 10）： 1 399.
4Graham DY, Opekun AR, klein PD. Clarithromycin for the eradication of Helicobacter Pylori[J]. J Clin Grastr_oentrol, 1993, 16： 292.
5Yatsunami J, Turta N, Wakamatsu K, et al. Clarithrom_ ycin is a poten inhibitor of tumor-indaceel angiogene_ sis[J]. Res Exp Med（ Berl）,1997, 197（ 4）： 189.
